Understanding how certain proteins influence the growth of lymphatic vessels
Elucidating the GPCR protein networks that drive lymphatic growth
This study is looking at how a special protein called adrenomedullin helps form lymphatic vessels, which is important for treating lymphatic diseases that affect many people, with the hope of finding new ways to help those who currently have limited treatment options.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10912495 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind lymphatic vessel formation, which is crucial for managing various lymphatic diseases affecting millions globally. The study focuses on a specific peptide called adrenomedullin and its interaction with proteins that help regulate the growth and movement of lymphatic cells. By exploring these protein networks, the research aims to identify potential therapeutic targets for developing new treatments for lymphatic disorders. Patients may benefit from insights that could lead to effective pharmacological interventions for conditions currently lacking approved treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from lymphatic diseases characterized by dysfunctional lymphatic vessel development.
Not a fit: Patients with lymphatic conditions that are not related to the mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for lymphatic diseases, improving patient outcomes and quality of life.
How similar studies have performed: While the specific approach of targeting these protein interactions is novel, similar research has shown promise in understanding lymphatic biology and developing treatments for related conditions.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Serafin, Donald Stephen — Univ of North Carolina Chapel Hill
- Study coordinator: Serafin, Donald Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.